She seemed happier. We experienced joy. There were still moments of connection.
For the millions of families navigating the final chapters of dementia, agitation has long been an unrelenting presence met only by blunt and imperfect tools. On July 14, 2026, researchers presented findings from the LiBBY trial suggesting that a carefully formulated THC-CBD combination may offer something the existing pharmacopeia rarely has: meaningful relief, with nearly 90 percent of treated patients showing reduced agitation over twelve weeks. The discovery does not yet translate into something families can access, but it opens a door that has long been sealed shut.
- Late-stage dementia agitation strips patients of peace and caregivers of endurance, yet the drugs long used to manage it—morphine, Haldol, Valium—offer little relief and often compound the suffering.
- The LiBBY trial enrolled 120 hospice-eligible dementia patients across ten medical centers, testing a precisely formulated THC-CBD oil against placebo in a rigorous double-blind design.
- After just two weeks, 83.9% of those receiving the active treatment showed measurable improvement in agitation versus only 30.5% on placebo—a gap that widened further by week twelve.
- Safety data offered reassurance: adverse event rates were nearly identical between the treatment and placebo groups, suggesting the formulation did not add meaningful harm to an already vulnerable population.
- Researchers are drawing a firm line between their pharmaceutical-grade formulation and commercial cannabis products, warning that dispensary offerings cannot be assumed equivalent and that regulatory translation remains ahead.
In late-stage dementia, agitation is a relentless presence—restlessness, aggression, and emotional distress that exhaust both patients and those who love them. For decades, the medical response has relied on drugs like morphine, Valium, and Haldol, which work poorly and often leave patients more confused or sedated. Findings presented in July 2026 from the LiBBY trial suggest a different path may exist.
The trial enrolled 120 people with Alzheimer's or related dementias who were hospice-eligible and experiencing agitation, with an average age of 80. Half received a carefully formulated THC-CBD oil suspension; half received placebo. Neither patients, caregivers, nor clinicians knew who received which. Ten medical centers conducted visits in participants' homes and residential facilities.
The results were striking. After two weeks, 83.9 percent of those in the treatment group showed reduced agitation compared to just 30.5 percent on placebo. By twelve weeks, those figures shifted to 87.2 percent versus 23.6 percent—close to 90 percent of treated patients showing overall improvement. Co-lead investigator Jacobo Mintzer called the response rate extraordinary, noting that such numbers are rarely seen in clinical trials. Crucially, adverse event rates were nearly identical across both groups, suggesting the treatment did not add meaningful risk.
One family's account gives texture to the statistics. Laura, whose mother participated without knowing her assignment, noticed something change during visits. "She seemed happier," she said. "We experienced joy. There were still moments of connection." That language—joy, connection—names precisely what agitation steals.
Researchers are careful, however, to separate hope from premature action. The formulation tested was precisely manufactured under close medical supervision and bears little resemblance to products available at dispensaries or online. Co-lead investigator Brigid Reynolds was direct: commercial products should not be assumed equivalent. Before families facing late-stage dementia can access this treatment, further development, regulatory approval, and clinical translation will be required.
In late-stage dementia, agitation arrives like an unwelcome storm—restlessness, aggression, emotional distress that wears down both the person living with the disease and everyone trying to care for them. For decades, doctors have reached for the same limited toolkit: morphine, Valium, Haldol. These drugs work poorly and often leave patients worse off, drowsy or confused or both. On July 14, 2026, researchers presented findings from a trial that suggests a different path forward.
The LiBBY trial—named for the Life's end Benefits of cannaBidiol and tetrahYdrocannabinol—enrolled 120 people with Alzheimer's disease or other forms of dementia who were hospice-eligible and experiencing agitation. Ten medical centers across the country ran the study, conducting visits in participants' homes or residential facilities. The average age was 80. Half received a carefully formulated combination of THC and CBD delivered as a rapid-acting oil suspension taken by mouth. The other half received placebo. Neither the patients, their caregivers, nor the clinicians knew who got what.
The results were striking. Using a detailed 29-factor agitation assessment tool called the Cohen-Mansfield Agitation Inventory, researchers measured change at two weeks and again at twelve weeks. After just two weeks, the THC-CBD group showed a 6.27-point reduction in mean agitation scores compared to placebo. By week twelve, the improvement held steady. When researchers looked at a separate measure—the Clinical Global Impression of Change in Behavior assessment—the gap widened further. At two weeks, 83.9 percent of people receiving the active treatment showed less agitation, compared to 30.5 percent in the placebo group. At twelve weeks, those numbers were 87.2 percent versus 23.6 percent. Close to 90 percent of study participants who received the treatment showed overall improvement. Jacobo Mintzer, the co-lead investigator from the Medical University of South Carolina and Georgetown University, called the response rate extraordinary. "Rarely do we see close to 90% of patients in a trial respond positively to a new medication," he said.
The safety profile was reassuring. Adverse events—infections, gastrointestinal problems, the sorts of complications common in this population—occurred at similar rates in both groups: 46.7 percent in the treatment arm, 42.4 percent in placebo. Nothing unexpected emerged. Brigid Reynolds, the other co-lead investigator, framed the findings in the context of real suffering. "Agitation affects many people with late-stage dementia," she explained. "Current treatment options are limited and often carry significant side effects, underscoring the need for safer, more effective therapies."
One family's experience hints at what these numbers might mean in practice. Laura, whose mother participated in the trial, did not know whether her mother received the active medication or placebo. But she noticed something shift during her visits. "She seemed happier," Laura said. "We experienced joy. There were still moments of connection." That language—joy, connection—captures what gets lost in agitation and what these results might restore.
Yet the researchers are careful to draw a bright line between what they studied and what people can buy. The formulation tested in the LiBBY trial was precisely manufactured and administered under close medical supervision. Commercial THC and CBD products—available at dispensaries, online, over the counter—vary wildly in composition, quality, and dosing. Reynolds was direct: "People should not assume that products available at dispensaries or online are equivalent to what was studied in this trial." The medication in this research was not the same as what sits on a shelf. That distinction matters enormously, because it means the hope these results offer cannot simply be purchased at a local shop. It will require further development, regulatory approval, and clinical translation before families facing late-stage dementia might actually access this treatment.
Notable Quotes
Rarely do we see close to 90% of patients in a trial respond positively to a new medication.— Jacobo Mintzer, co-lead investigator
People should not assume that products available at dispensaries or online are equivalent to what was studied in this trial.— Brigid Reynolds, co-lead investigator
The Hearth Conversation Another angle on the story
Why does agitation in late-stage dementia matter so much? It's one symptom among many.
Because it's the one that breaks caregivers. Restlessness, aggression, emotional distress—these aren't just uncomfortable for the person living with dementia. They exhaust the people trying to keep them safe and comfortable. Agitation is what makes families feel helpless.
And the current drugs—morphine, Valium, Haldol—they don't work?
They work poorly and they carry their own burden. You're trading one problem for another. That's why a 90 percent response rate in a trial is so unusual. Researchers almost never see that kind of improvement.
But you're emphasizing that this isn't the same as buying CBD oil online.
It's completely different. This was a medical formulation, carefully dosed, administered under supervision. The commercial stuff varies so much—in strength, in purity, in what's actually in the bottle—that you can't assume it would work the same way or be safe.
So what happens next?
That's the open question. The trial results are encouraging, but now it has to move through the regulatory process. It has to be manufactured consistently. Doctors have to learn how to prescribe it. Families have to be able to access it. Right now, it's a proof of concept.
For someone whose parent is experiencing agitation right now, what should they know?
That there's real research happening, that better options may exist. But not to assume that over-the-counter products will deliver the same benefit. Talk to their doctor about what's actually available today, and stay informed about what's coming.